U.S. markets close in 5 hours 54 minutes
  • S&P 500

    3,665.07
    -79.45 (-2.12%)
     
  • Dow 30

    29,428.99
    -497.95 (-1.66%)
     
  • Nasdaq

    10,770.43
    -302.88 (-2.74%)
     
  • Russell 2000

    1,720.39
    -32.13 (-1.83%)
     
  • Crude Oil

    90.42
    +1.97 (+2.23%)
     
  • Gold

    1,706.80
    -14.00 (-0.81%)
     
  • Silver

    20.33
    -0.33 (-1.57%)
     
  • EUR/USD

    0.9752
    -0.0043 (-0.44%)
     
  • 10-Yr Bond

    3.8980
    +0.0720 (+1.88%)
     
  • GBP/USD

    1.1111
    -0.0057 (-0.51%)
     
  • USD/JPY

    145.2060
    +0.1380 (+0.10%)
     
  • BTC-USD

    19,599.84
    -504.40 (-2.51%)
     
  • CMC Crypto 200

    446.53
    -8.49 (-1.87%)
     
  • FTSE 100

    6,977.69
    -19.58 (-0.28%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting

·1 min read
  • AstraZeneca Plc (NASDAQ: AZN) has reported preliminary results from the SAVANNAH Phase 2 trial of Tagrisso (osimertinib) plus savolitinib in epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, whose disease progressed on Tagrisso.

  • Tagrisso plus savolitinib demonstrated an objective response rate (ORR) of 49%.

  • The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52%).

  • In patients whose tumors did not show high levels of MET, the ORR was 9%.

  • Savolitinib, marketed in China under Orpathys, is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) jointly developed and commercialized by AstraZeneca and HUTCHMED (China) Ltd (NASDAQ: HCM).

  • The safety profile of Tagrisso plus savolitinib was consistent with the known profiles of the combination and each treatment alone. No new safety signals were identified.

  • The global SAFFRON Phase 3 trial will further assess the Tagrisso plus savolitinib combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following Tagrisso.

  • Price Action: AZN shares are down 0.44% at $65.74 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.